ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005046

immune system disorder

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. immune system disorder. Diseases, record MONDO_0005046. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005046

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
immune system disorder
Open Targets
Open Targets ID
MONDO_0005046
Open Targets
Other names
AUTOIMMUNE DISEASE NEC, Autoimmune disease, not elsewhere classified, DEFIC CELL IMMUNITY NOS, Deficiency of cell-mediated immunity, Disorder of the immune mechanism NOS, Disorder of the immune mechanism NOS (disorder), Disorders involving the immune mechanism, IMMUNDEF T-CELL DEF NOS, IMMUNE MECHANISM DIS NEC, IMMUNE MECHANISM DIS NOS, Immune System and Related Disorders, Immunodeficiency and Immunosuppression Disorders, Immunodeficiency with predominant T-cell defect, unspecified, Other deficiency of cell-mediated immunity, Other specified disorders involving the immune mechanism, Other specified disorders of the immune mechanism, Other specified disorders of the immune mechanism (disorder), Unspecified disorder of immune mechanism, [X]Disorder involving the immune mechanism, unspecified, [X]Disorder involving the immune mechanism, unspecified (disorder), autoimmune diseases, disease of immune system, disease or disorder of immune system, disorder of immune system, immune disease, immune disorder, immune dysfunction, immune system disease, immune system disease or disorder
Open Targets
Disease Ontology
DOID:2914
Disease Ontology
MeSH
D007154
MeSH
NCI Thesaurus
C3507
NCI Thesaurus
Highest stage of its drugs
Approval, for 65 of its 86 drugs, from ATC, EMA Human Drugs and TTD
Open Targets

Drugs86

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
HUMAN IMMUNOGLOBULIN GCHEMBL1201599ApprovalTTD300Drugs and targets
SPESOLIMABCHEMBL4297911AntibodyApprovalATC200Drugs and targets
ABATACEPTCHEMBL1201823ProteinApprovalATC100Drugs and targets
ABETIMUSCHEMBL2108171ApprovalATC100Drugs and targets
ACTARITCHEMBL1885632Small moleculeApprovalTTD100Drugs and targets
ADALIMUMABCHEMBL1201580AntibodyApprovalATC100Drugs and targets
AFELIMOMABCHEMBL2108887AntibodyApprovalATC100Drugs and targets
ALEFACEPTCHEMBL1201571ProteinApprovalATC100Drugs and targets
AMIFAMPRIDINECHEMBL354077Small moleculeApprovalEMA Human Drugs100Drugs and targets
ANAKINRACHEMBL1201570ProteinApprovalATC100Drugs and targets

1 to 10 of 86

See all 86 drugs

Targets84

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
IL12BInterleukin-126Interleukin-12 inhibitor; Interleukin-23 inhibitorApprovalhttps://conductscience.org/library/genes/3593Drugs and targets
IL23AInterleukin-236Interleukin-23 inhibitorApprovalhttps://conductscience.org/library/genes/51561Drugs and targets
TNFTumor necrosis factor6TNF-alpha inhibitorApprovalhttps://conductscience.org/library/genes/7124Drugs and targets
IL6RIL6Ralpha/GP1304IL6Ralpha/GP130 antagonist; Interleukin-6 receptor alpha subunit antagonist; Interleukin-6 receptor alpha subunit inhibitorApprovalhttps://conductscience.org/library/genes/3570Drugs and targets
CRBNCRL4(CRBN) E3 ubiquitin ligase3CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulatorApprovalhttps://conductscience.org/library/genes/51185Drugs and targets
CUL4ACRL4(CRBN) E3 ubiquitin ligase3CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulatorApprovalhttps://conductscience.org/library/genes/8451Drugs and targets
DDB1CRL4(CRBN) E3 ubiquitin ligase3CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulatorApprovalhttps://conductscience.org/library/genes/1642Drugs and targets
IL17AInterleukin-17A3Interleukin 17A inhibitorApprovalhttps://conductscience.org/library/genes/3605Drugs and targets
IL1BInterleukin-1 beta3Interleukin-1 beta inhibitorApprovalhttps://conductscience.org/library/genes/3553Drugs and targets
IL6Interleukin-63Interleukin-6 antagonist; Interleukin-6 inhibitorApprovalhttps://conductscience.org/library/genes/3569Drugs and targets

1 to 10 of 84

See all 84 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00598481ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCIDPhase 2122020-07-31Immunologic Deficiency SyndromesBUSULFANIts record names the diseaseClinicalTrials.gov
NCT05787574A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory ConditionPhase 239Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System DiseasesDEXAMETHASONE, EMAPALUMAB, FLUDARABINEOpen Targets' reading of its recordClinicalTrials.gov
NCT05116215To Evaluate the Safety of Treating Autoimmune Diseases With Molecular Hydrogen SupplementPhase 127Autoimmune DiseasesHYDROGENIts record names the diseaseClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
38355973DERIVED1PubMed
28319446DERIVED1PubMed
27129325DERIVED1PubMed
22184407DERIVED1PubMed
19652199DERIVED1PubMed
19633200DERIVED1PubMed
19179314DERIVED1PubMed
18218852DERIVED1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005046

GET https://conductscience.org/api/diseases/v1/MONDO_0005046/drugs?page=2

API referenceFor AI assistants